Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug 22:55:101486.
doi: 10.1016/j.gore.2024.101486. eCollection 2024 Oct.

Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature

Joshua Clark  1 , Andrew Blake  1 , Scott Vasher  1 , Richard C Boucher  1 , Alexis R Jones  2 , Hee Jae Choi  1 , Benjamin B Albright  2
Affiliations
Case Reports

Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature

Joshua Clark et al. Gynecol Oncol Rep. .

Abstract

•Mirvetuximab soravtansine-gynx should be recognized as a cause of drug-induced interstitial lung disease (ILD).•Radiographic manifestations of mirvetuximab soravtansine-gyn induced ILD include organizing pneumonia pattern.•Interstitial lung disease related to mirvetuximab soravtansine-gyn can cause high morbidity.•Corticosteroids are commonly used in drug-induced interstitial lung disease and should be considered when encountering ILD related to mirvetuximab.•Changes to manufacturer dosing guidelines for grade 1 pneumonitis related to mirvetuximab soravtansine-gyn need to be considered.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Cross sectional imaging.
Fig. 1
Fig. 1
Cross sectional imaging.
Fig. 1
Fig. 1
Cross sectional imaging.
Fig. 1
Fig. 1
Cross sectional imaging.
See this image and copyright information in PMC

References

    1. Bogani G., Coleman R.L., Vergote I., et al. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int. J. Gynecol. Cancer. 2024;34(4):469–477. doi: 10.1136/ijgc-2023-004924. - DOI - PubMed
    1. Camus P., Bonniaud P., Fanton A., Camus C., Baudaun N., Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clin. Chest Med. 2004;25(3) doi: 10.1016/j.ccm.2004.05.006. pp. 479–519, vi. - DOI - PubMed
    1. Conte P., Ascierto P.A., Patelli G., et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2) doi: 10.1016/j.esmoop.2022.100404. - DOI - PMC - PubMed
    1. Cristea M.C., Stewart D., Synold T., et al. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol. Oncol. 2024;182:124–131. doi: 10.1016/j.ygyno.2023.12.017. - DOI - PubMed
    1. Elahere. Prescribing Information (Package Insert). ImmunoGen Inc. Published online March 1, 2024. Accessed June 1, 2024. https://elahere.com/pdf/prescribing-information.pdf.

Publication types

LinkOut - more resources